Le Lézard
Classified in: Ebola virus
Subject: SVY

Global Ebola Partnering 2010 to 2017



LONDON, Nov. 22, 2017 /PRNewswire/ --

Download the full report: https://www.reportbuyer.com/product/3605724

? Trends in partnering deals
? Top deals by value
? Deals listed by company A-Z, industry sector, stage of development, technology type

The report provides understanding and access to the partnering deals and agreements entered into by the world's leading healthcare companies.

The report provides an analysis of partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered ? contract documents provide this insight where press releases do not.

This data driven report contains multiple links to online copies of actual deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of partnering trends.

Chapter 1 provides an overview of the trends in partnering since 2010, including a summary of deals by industry sector, stage of development, deal type, and technology type.

Chapter 2 provides a review of the top 10 most active companies in the therapy area, including a comprehensive listing of the deals announced by each company.

Chapter 3 provides a comprehensive directory of partnering deals signed and announced since 2010. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

Chapter 4 provides a listing of partnering deals where a contract document is available alongside the deal record.

Chapters 5 and 6 provide a summary of M&A deals since 2010 where the acquired company is active in the therapy area of interest.

Chapters 7 and 8 provide a summary of financings since 2010 where the financed company is active in the therapy area of interest.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of technologies and products in the therapy area.

Download the full report: https://www.reportbuyer.com/product/3605724

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

 

SOURCE ReportBuyer


These press releases may also interest you

19 jui 2018
Soligenix, Inc. (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today issued an update letter from its President and...

19 jui 2018
GRANTS PASS, Ore., July 19, 2018 /PRNewswire-PRWeb/ -- For several days, the world watched and prayed as brave rescuers battled to save a dozen Thai soccer players and their coach from a flooded cave in northwestern Thailand. The boys and the coach...

19 jui 2018
Alrik Danielson, President and CEO: "Our record start to 2018 has continued. Sales grew by 9% organically, to SEK 22.6 billion and our operating profit was SEK 2,925 million ? SKF's highest reported quarterly profit to date. Our operating margin, at...

19 jui 2018
"Demand in our main markets was solid in the second quarter of 2018, and both our vehicle and service business continued to grow at a good pace. Our net sales increased by 18% to SEK 104 billion, we improved the adjusted operating income by SEK 3...

19 jui 2018
JANUARY 1 ? JUNE 30, 2018(compared with the corresponding period a year ago) Net sales increased 8.1% to SEK 57,741m (53,423) Organic net sales, which exclude exchange rate effects, acquisitions and divestments, increased 2.8% Operating profit...

18 jui 2018
This report analyzes the worldwide markets for Disinfectants in US$ by the following Delivery Systems and End-use Applications: Delivery Systems - Aerosols, and Non-Aerosols; End-use Applications - Industrial & Institutional, Healthcare, and...




News published on 22 november 2017 at 15:53 and distributed by: